Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rec

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target […]

Related Keywords

Robertw Baird , Michael Mason , Reshma Rangwala , Piper Sandler , Nasdaq , Karyopharm Therapeutics Inc , Marshall Wace , Morgan Stanley , Its Selective Inhibitor Of Nuclear Export , Armistice Capital , Karyopharm Therapeutics , Get Rating , Partners Management , Street Corp , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti , Kpti , Medical , Ratings , Consensus ,